Cambridge Investment Research Advisors, Inc. Humacyte, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Humacyte, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 15,688 shares of HUMA stock, worth $52,084. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,688
Previous 13,300
17.95%
Holding current value
$52,084
Previous $72,000
9.72%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HUMA
# of Institutions
172Shares Held
41MCall Options Held
553KPut Options Held
942K-
Black Rock Inc. New York, NY7.14MShares$23.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$18.6 Million0.0% of portfolio
-
State Street Corp Boston, MA4.61MShares$15.3 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.85MShares$9.46 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA2.14MShares$7.09 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $342M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...